Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
Bio Preventive Medicine and Precision Diabetes presented new data from the CREDENCE trial at the American Diabetes Association sessions. The findings suggest that the DNlite™ biomarker can independently predict renal risk in patients with type 2 diabetes and chronic kidney disease.
Why it matters
This advancement in diagnostic testing could improve clinical outcomes for diabetic patients by identifying renal risks earlier than conventional methods.
New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney disease
The content is a standard corporate press release regarding medical research findings.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in